Seroquel and Seroquel XR approved for new indications in bipolar disorder in EU
This article was originally published in Scrip
AstraZeneca'santipsychotic Seroquel (quetiapine fumarate) and the once-a-day extended release formulation, Seroquel XR, have received approval for the treatment of major depressive episodes in bipolar disorder via the European mutual recognition procedure (MRP). Additionally, Seroquel XR has been licensed for moderate to severe manic episodes in bipolar disorder.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.